Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
PMDA Generic GMP Inspections a Real-World Test to Stem Startup Risks: Official
Japan’s upcoming shift of GMP inspections for newly approved generics to the Pharmaceuticals and Medical Devices Agency (PMDA) will serve as a real-world test of whether closer coordination between regulatory reviews and manufacturing oversight can head off quality problems at…
To read the full story
Related Article
- Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
- MHLW Seeks to Raise Quality of Prefectural Generic GMP Inspections
September 8, 2025
- Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
- PMDA-Led Inspections Will Help Straighten Up Generic Makers: MHLW Councilor
September 6, 2024
- MHLW Sets Out to Beef Up Inspector Skills with Nationwide Sharing of GMP Reports
February 29, 2024
REGULATORY
- PMDA Suspends Review Specialist for 3 Days over Lost USB
September 28, 2026
- Japan Doles Out Orphan Tags to Givinostat, Apitegromab, and Lots More
September 28, 2026
- MHLW Pharma Chief Eyes Wider Use of English Drug Filings to Stem Drug Loss
September 25, 2026
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…